^
No biomarker
SCCHN
cisplatin + 5-fluorouracil + docetaxel
Sensitive: A1 - Approval
No biomarker
SCCHN
nivolumab
Sensitive: A1 - Approval
No biomarker
SCCHN
TPF
Sensitive: A1 - Approval
PD-L1 expression
SCCHN
pembrolizumab
Sensitive: A1 - Approval
No biomarker
SCCHN
cetuximab
Sensitive: A1 - Approval
No biomarker
SCCHN
pembrolizumab
Sensitive: A1 - Approval
PD-L1 expression
SCCHN
pembrolizumab
Sensitive: A1 - Approval
No biomarker
SCCHN
methotrexate
Sensitive: A2 - Guideline
PD-L1 negative
SCCHN
methotrexate
Sensitive: A2 - Guideline
PD-L1 negative
SCCHN
TPeX
Sensitive: A2 - Guideline
PD-L1 negative
SCCHN
pembrolizumab
Sensitive: A2 - Guideline
PD-L1 negative
SCCHN
cetuximab
Sensitive: A2 - Guideline
PD-L1 negative
SCCHN
5-fluorouracil
Sensitive: A2 - Guideline
PD-L1 expression
SCCHN
ADX-2191
Sensitive: A2 - Guideline
PD-L1 expression
SCCHN
cetuximab
Sensitive: A2 - Guideline
PD-L1 expression
SCCHN
5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
SCCHN
TPeX
Sensitive: A2 - Guideline
No biomarker
SCCHN
cisplatin
Sensitive: A2 - Guideline
No biomarker
SCCHN
5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
SCCHN
pembrolizumab + nivolumab
Sensitive: A2 - Guideline
No biomarker
SCCHN
AT-406
Sensitive: B - Late Trials
CDKN2A negative
SCCHN
panitumumab
Sensitive: B - Late Trials
HRAS mutation
SCCHN
tipifarnib
Sensitive: B - Late Trials
TMB-H
SCCHN
durvalumab
Sensitive: B - Late Trials
TMB-H
SCCHN
pembrolizumab
Sensitive: B - Late Trials
TMB-H
SCCHN
durvalumab + CP-675206
Sensitive: B - Late Trials
KMT2D mutation
SCCHN
durvalumab + CP-675206
Sensitive: B - Late Trials
EGFR amplification
SCCHN
afatinib
Sensitive: B - Late Trials
ERBB3-L
SCCHN
afatinib
Sensitive: B - Late Trials
CDKN2A negative
SCCHN
afatinib
Sensitive: B - Late Trials
PTEN-H
SCCHN
afatinib
Sensitive: B - Late Trials
PD-L1 overexpression
SCCHN
durvalumab
Sensitive: B - Late Trials
ATM mutation
SCCHN
durvalumab + CP-675206
Sensitive: B - Late Trials
No biomarker
SCCHN
IMP 321
Sensitive: B - Late Trials
PD-L1 expression
SCCHN
nivolumab + ipilimumab
Sensitive: B - Late Trials
PD-L1 expression
SCCHN
durvalumab
Sensitive: C1 - Off-label
EGFR expression
SCCHN
cetuximab
Sensitive: C1 - Off-label
EGFR overexpression
SCCHN
cetuximab
Sensitive: C2 – Inclusion Criteria
TP53 mutation
SCCHN
AZD1775
Sensitive: C2 – Inclusion Criteria
PD-L1 expression
SCCHN
pembrolizumab + GSK3359609
Sensitive: C2 – Inclusion Criteria
PD-L1 expression
SCCHN
nivolumab
Sensitive: C2 – Inclusion Criteria
PD-L1 overexpression
SCCHN
pembrolizumab
Sensitive: C2 – Inclusion Criteria
PIK3CA mutation
SCCHN
alpelisib
Sensitive: C2 – Inclusion Criteria
PD-L1 expression
SCCHN
durvalumab + CP-675206
Sensitive: C2 – Inclusion Criteria
EGFR amplification
SCCHN
Immunotherapy
Resistant: C3 – Early Trials
PRSS3 underexpression
SCCHN
cetuximab
Sensitive: C3 – Early Trials
TET1 mutation
SCCHN
Immunotherapy
Sensitive: C3 – Early Trials
PD-L1 expression
SCCHN
pembrolizumab + IMP 321
Sensitive: C3 – Early Trials
EGFRvIII mutation
SCCHN
cetuximab
Resistant: C3 – Early Trials
AREG overexpression
SCCHN
cetuximab
Resistant: C3 – Early Trials
PIK3CA mutation
SCCHN
temsirolimus
Sensitive: C3 – Early Trials
EGFR mutation
SCCHN
cetuximab + ISU104
Sensitive: C3 – Early Trials
NRG1 mutation
SCCHN
cetuximab + ISU104
Sensitive: C3 – Early Trials
HER-2 mutation
SCCHN
cetuximab + ISU104
Sensitive: C3 – Early Trials
MET positive
SCCHN
nivolumab
Resistant: C3 – Early Trials
TP53 mutation
SCCHN
PD1 inhibitor
Sensitive: C3 – Early Trials
TMB-H
SCCHN
PD1 inhibitor
Sensitive: C3 – Early Trials
PD-L1 overexpression
SCCHN
PD1 inhibitor
Sensitive: C3 – Early Trials
PD-L1 underexpression
SCCHN
cetuximab sarotalocan
Sensitive: C3 – Early Trials
EGFR R521K
SCCHN
cetuximab
Resistant: C3 – Early Trials
DDR2 overexpression
SCCHN
dasatinib
Sensitive: C3 – Early Trials
ERBB3 mutation
SCCHN
cetuximab + ISU104
Sensitive: C3 – Early Trials
SMARCA4 mutation + MSI-L/dMMR
SCCHN
Immunotherapy
Resistant: C3 – Early Trials
ROS1 mutation + MSI-L/dMMR
SCCHN
Immunotherapy
Resistant: C3 – Early Trials
PD-L2 overexpression
SCCHN
pembrolizumab
Sensitive: C3 – Early Trials
Choline elevation
SCCHN
pembrolizumab
Sensitive: C3 – Early Trials
IFNG RNA sig
SCCHN
pembrolizumab
Sensitive: C3 – Early Trials
IL1A elevation
SCCHN
cetuximab
Sensitive: C3 – Early Trials
FGFR overexpression
SCCHN
BAY1163877
Sensitive: C3 – Early Trials
CXCL8 expression
SCCHN
pembrolizumab
Resistant: C3 – Early Trials
MET N375S
SCCHN
afatinib
Sensitive: C3 – Early Trials
PIK3CA mutation
SCCHN
cetuximab
Resistant: C3 – Early Trials
PTEN expression
SCCHN
cetuximab
Resistant: C3 – Early Trials
KRAS mutation
SCCHN
cetuximab
Resistant: C3 – Early Trials
HRAS mutation
SCCHN
cetuximab
Resistant: C3 – Early Trials
PD-L1 overexpression
SCCHN
olaparib
Resistant: C3 – Early Trials
PD-L1 overexpression
SCCHN
durvalumab + CP-675206
Sensitive: C3 – Early Trials
ATM mutation
SCCHN
durvalumab
Sensitive: C3 – Early Trials
AREG expression
SCCHN
cetuximab
Sensitive: C3 – Early Trials
SMAD4 expression
SCCHN
cetuximab
Sensitive: C3 – Early Trials
TLR4 overexpression
SCCHN
cetuximab
Resistant: C3 – Early Trials
PIK3CA E542K
SCCHN
GDC-0980
Sensitive: C3 – Early Trials
PIK3CA mutation
SCCHN
cetuximab + alpelisib
Sensitive: C3 – Early Trials
FANCI mutation + FLT1 mutation
SCCHN
BKM120
Sensitive: C3 – Early Trials
FANCA mutation + FGFR3 mutation
SCCHN
BKM120
Sensitive: C3 – Early Trials
FANCD2 mutation + EP300 mutation
SCCHN
BKM120
Sensitive: C3 – Early Trials
PIK3CA mutation + EP300 mutation
SCCHN
BKM120
Sensitive: C3 – Early Trials
IFNG overexpression
SCCHN
pembrolizumab
Sensitive: C3 – Early Trials
IDO1 overexpression
SCCHN
pembrolizumab
Sensitive: C3 – Early Trials
IFI35 overexpression
SCCHN
pembrolizumab
Sensitive: C3 – Early Trials
OASL overexpression
SCCHN
pembrolizumab
Sensitive: C3 – Early Trials
CXCL9 overexpression
SCCHN
pembrolizumab
Sensitive: C3 – Early Trials